Posting: # 18878
I was looking into the abstracts published after annual PAGE meeting (and had a pleasure to discuss it with some authors).
I collected some of them here for your review:
1. In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone
2. Automatic framework for bioequivalence studies from In Vitro test to In Vivo study design
3. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles
4. Selecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies
5. Bayesian knowledge integration for an in vitro–in vivo correlation (IVIVC) model
The investigators are actively trying to raise the level of the models from in vivo level to in vitro in vivo level.
AFAIK regulatories are also interested and funding some of them.
What do you think? Is time of deconvolution over? Could we see new class A IVIVC using that approach soon?
Posting: # 18894
» What do you think? Is time of deconvolution over? Could we see new class A IVIVC using that approach soon?
Afraid so (more or less). I spoke w my former boss who is now working in FDA and he told me about it...